Lupus low disease activity state attainment in the phase 3 TULIP trials of anifrolumab in active systemic lupus erythematosus

Review Rheumatology

Measurement of specific organ domains in lupus randomized controlled trials: a scoping review

Kathryn Connelly et al.

Summary: In randomized controlled trials for systemic lupus erythematosus (SLE), musculoskeletal and mucocutaneous manifestations are predominant, and organ-specific outcome measures are commonly reported but their definitions vary.

RHEUMATOLOGY (2022)

Add to Collection

Article Rheumatology

Type 1 interferon status in systemic lupus erythematosus: a longitudinal analysis

Melissa Northcott et al.

Summary: This study found that ISG levels are stable over time in the majority of SLE patients and do not correlate with disease activity, although IFN high status is associated with more severe SLE. High-dose glucocorticoids can suppress ISG expression, while routine dose does not.

LUPUS SCIENCE & MEDICINE (2022)

Add to Collection

Article Rheumatology

Phase III/IV, Randomized, Fifty-Two-Week Study of the Efficacy and Safety of Belimumab in Patients of Black African Ancestry With Systemic Lupus Erythematosus

Ellen Ginzler et al.

Summary: The study aimed to assess the efficacy and safety of intravenous belimumab plus standard therapy in patients of self-identified Black race with systemic lupus erythematosus. While the primary endpoint was not achieved, numerical improvements favoring belimumab were observed, especially in patients with high disease activity or renal manifestations. The safety profile of belimumab was consistent with previous SLE trials.

ARTHRITIS & RHEUMATOLOGY (2022)

Add to Collection

Article Rheumatology

Anifrolumab reduces flare rates in patients with moderate to severe systemic lupus erythematosus

Richard Furie et al.

Summary: The analysis of pooled data from the TULIP-1 and TULIP-2 trials supports that anifrolumab reduces flares and allows for glucocorticoid tapering in patients with SLE, especially for those who successfully taper to <= 7.5 mg/day.

LUPUS (2021)

Add to Collection

Article Rheumatology

2021 DORIS definition of remission in SLE: final recommendations from an international task force

Ronald F. van Vollenhoven et al.

Summary: Through systematic literature reviews and data analysis, the DORIS Task Force reached a consensus on a single definition of remission in SLE, recommending criteria based on specific clinical indicators and medication dosage.

LUPUS SCIENCE & MEDICINE (2021)

Add to Collection

Article Rheumatology

Safety profile of anifrolumab in patients with active SLE: an integrated analysis of phase II and III trials

Raj Tummala et al.

Summary: In a pooled analysis of 925 patients with moderate to severe SLE, monthly intravenous anifrolumab 300 mg was generally well tolerated over 52 weeks with an acceptable safety profile. Anifrolumab was associated with an increased incidence of herpes zoster and respiratory tract infections, but a lower reported rate of SLE worsening as serious adverse events.

LUPUS SCIENCE & MEDICINE (2021)

Add to Collection

Article Rheumatology